Arginine Therapy for Pain in Sickle Cell Disease: A Phase‐2 Randomized, Placebo‐Controlled Trial is a research paper published in American Journal of Hematology (2025). On theSindex it has a DataRank of 0.396. It has been cited 8 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.0660
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 6 citers.
NIH HHS
Grant: K08AI166837
NHLBI NIH HHS
Grant: K23 HL173694
U.S. Food and Drug Administration
Grant: R01FD004814‐01A2
FDA HHS
Grant: R01 FD004814
NCCIH NIH HHS
Grant: K24 AT009893
National Center for Complementary and Integrative Health (NCCIH)
Grant: K24AT009893-01
FDA HHS
Grant: R01FD004814-01A2
National Center for Complementary and Integrative Health
Grant: K24AT009893‐01
FWCI
7.71
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals